Organic Active Ingredients TRIZ Cases

Using cannabinoid-reduced cannabis residue alone or with hempseed hull, this case shows a new prebiotic source that promotes beneficial gut microbes.

A metformin and Chir99021 combination suppresses collagen deposition and inflammation to treat fibrosis and limit tissue damage.

A one-pot sequence merges phosphorane formation and Wittig reaction to raise benzopyranone yield, cut impurities, and support scale-up.

Brain-region Aβ and tau interaction scores help predict Alzheimer's treatment response and support more personalized therapy selection.

Targeted RNAi silences XDH expression in hepatocytes, offering urate lowering for gout and hyperuricemia with fewer side effects.

A benzoimidazole sulphate salt protects motor neurons and neuromuscular junctions by modulating Tau, progranulin, and TDP-43.

A six-strain probiotic with glutamine targets the gut-brain axis to ease OCD symptoms when standard antidepressants show limited response.

Poziotinib overcomes steric hindrance and TKI resistance in HER2 exon 21 mutant cancers, enabling potent low-dose inhibition and tumor regression.

A dual MDH1/MDH2 inhibitor blocks mitochondrial respiration and cancer cell growth by disrupting a key metabolic pathway.

An aqueous flocculated suspension using sorbitan esters and polysorbate 20 improves antipsychotic injectability, resuspendability, and site tolerance.

Synthetic kava analogs inhibit TNF-α and reduce inflammation, offering a lower-cost alternative to biologics for periodontitis and arthritis.

A selective amide scaffold targets JAK1 while sparing JAK2, aiming to treat JAK1-mediated disease with lower dose-limiting toxicity.

A buffered micronized apixaban suspension avoids surfactants and phase change while preserving crystallinity, dissolution, and oral stability.

Mesoporous zirconia carriers load and release antimicrobials inside biofilms, improving eradication while lowering dose and side effects.

Retinal viral-vector delivery with cell-specific promoters targets locus coeruleus pathways without direct brain surgery for nervous system disorders.

Novel endocyclic pyrimidinone compounds inhibit Lp-PLA2 to reduce oxidative stress and inflammation in neurodegenerative and cardiovascular disease.

Camphorquinone-initiated hyaluronic acid hydrogel extends joint residence and lubrication while avoiding toxic crosslinker purification.

A saliva-permeable nicotine pouch uses water-insoluble fiber and alkaline pH control to speed release while staying small and discreet.

A hydrophilic core in a hydrophobic phase uses osmotic pressure to stabilize nicotine release and improve absorption consistency.

A novel resiquimod monosulfate anhydrate crystal form improves stability, dissolution consistency, and bioavailability for cancer treatment.

Positively charged ruthenium complexes use 3D binding geometry to improve galectin-1 selectivity and inhibition for cancer, fibrosis, and HIV.

Selective imidazopyridine and triazolopyridine TLR9 inhibitors address fibrosis while improving stability, bioavailability, and side-effect control.

A novel compound BAB159 and its polymyxin E combination address multidrug resistance with broad-spectrum antibacterial and antifungal activity.

RAC2 G12V delivery ablates hematopoiesis for bone marrow transplantation while avoiding the toxicity of chemotherapy and radiotherapy.

Specific indole amide compounds inhibit IDO to block tryptophan conversion, helping restore immune function across cancer and inflammatory disease.

Specific lithium benzoate cocrystals tune water solubility to extend lithium release while preserving bioavailability and reducing hygroscopicity.

Ester-linked tryptamine prodrugs improve oral bioavailability and stability, then hydrolyze in vivo to active 5HT2A agonists for depression.

Small molecules targeting a defined PCSK9 binding pocket enable oral LDL-C lowering with fewer antibody-related reactions.

Self-inactivating CRISPR-Cas vectors improve repeat-disorder editing by limiting expression time, reducing off-target activity, and preserving delivery efficiency.

Selective imidazoquinazoline A2A antagonists target motor symptoms in Parkinson's disease while aiming to limit non-motor side effects.

Peptide Smad3 inhibitors improve selectivity over small molecules to suppress cancer cell growth, invasion, and metastasis.

Strategic fluoro nucleotide placement improves blood and liver stability while maintaining hepatocyte-targeted gene silencing with fewer off-target effects.

Combined oral minoxidil and finasteride simplify hair loss treatment, improving compliance while enhancing hair growth and reducing shedding.

A resistant starch, oat beta-glucan, and resistant dextrin blend helps stabilize blood sugar, improve satiety, and support digestive health.

A Formula I compound paired with hyodeoxycholic acid helps restore ovarian function by lowering FSH, raising estrogen, and reducing oxidative stress.

Bifunctional compounds recruit E3 ligases to ubiquitinate and degrade tau protein, addressing the lack of effective tau-targeting therapies.

Novel isoquinolinone salt crystal forms improve membrane permeability and drug exposure, enabling longer-lasting intraocular pressure reduction.

Specific insulin chain modifications plus iloprost, citrate, EDTA, and polyphosphates speed absorption while limiting fibril formation.

mRNA encoding VZV antigens boosts earlier antibody responses and broader immunity while avoiding live-virus and DNA vaccine risks.

A single-serve d-mannose drink balances effective dosage with manageable liquid volume to improve timely use for urinary tract health.

A buffered naloxone nasal composition with glycerin improves storage stability while preserving rapid overdose reversal and easy repeat dosing.

CCR1 antagonists help inhibit pancreatic tumor growth and support patient stratification using CCR1 expression and macrophage infiltration.

Pyrido[2,3-d]pyrimidin-7-one compounds tune dual or selective RIPK2 and ALK2 inhibition to address inflammatory, bone, and cancer pathways.

A heterocyclic TRPC5 inhibitor case showing how structure changes improve liver microsome stability and clinical pharmacokinetic properties.

A PEG-tuned lipid nanoparticle enables low-invasive transnasal nucleic acid delivery to brain tissue while limiting liver accumulation.

Specific KRAS inhibitor compounds target G12C and G12D mutations to improve treatment potential across pancreatic, lung, and colorectal cancers.

A small-molecule inducer boosts secretion of correctly folded Z A1AT, addressing misfolding and low active A1AT levels in AATD.

Selective β2 receptor antagonist ICI 118,551 targets glioblastoma stemness and viability to delay progression despite resistance and BBB limits.

Novel BTK-targeting imidazopyridinone derivatives improve therapeutic efficacy while addressing variable patient response in autoimmune disease and cancer.

Modified oligonucleotides bind PLP1 RNA to lower toxic PLP1 expression and help relieve Pelizaeus-Merzbacher disease symptoms.

Local surfactant-budesonide delivery helps prevent BPD in preterm neonates while limiting systemic steroid side effects.

Adhesive unimolecular micelles are painted onto vessel adventitia to localize drug delivery and reduce intimal hyperplasia without bulky hydrogels.

Novel quinazoline derivatives inhibit FLT3 to expand targeted treatment options for acute myeloid leukemia.

A combined compound and bacterial-strain composition treats obesity by restoring gut microbiome balance and reducing food addiction.

Selective DDR1/DDR2 inhibitors use tetrahydrothienopyridine chemistry to improve inhalation profile and limit systemic exposure in lung fibrosis.

Selective receptor ligation targets overexpressed markers on virus-infected T lymphocytes to kill infected cells, lower viral load, and limit side effects.

A receptor-targeted exatecan ligand-drug conjugate improves solid tumor killing while reducing toxicity to normal cells.

Dual HDGF-VEGF targeting in one ocular antibody aims to curb abnormal cell and vascular growth with fewer limits than monthly anti-VEGF injections.

Formula I compounds selectively inhibit IRAK4 signaling to curb proinflammatory cytokine production in rheumatoid arthritis, tumors, and related disorders.

Small molecules selectively inhibit NIK to treat cancer and inflammatory disease while limiting broad immunosuppression.

Converting Compound A into a crystalline HCl salt resolves poor free-base stability and enables solid pharmaceutical dosage forms.

Targeting PARP7 with pyridazinone compounds helps reverse immune evasion by restoring Type I interferon signaling and T cell tumor killing.

A self-degrading Alvocidib prodrug enables remote liposome loading, sustained release, improved pharmacokinetics, and fewer side effects.

Topical CoQ10 helps chronic epidermolysis bullosa wounds shift from persistent inflammation to healing, reducing blister and wound size.

Heteroaryl methacrylic acids improve fumarate metabolic stability while reducing cytokine release and activating NRF2 for anti-inflammatory effects.

A polyphenol and high-DP oligosaccharide blend boosts Akkermansia and other beneficial gut bacteria while reducing GI discomfort.

Selective AKT-targeting compounds suppress cancer cell growth while avoiding the side effects and feedback issues seen with PI3K or mTOR inhibition.

Cyclodextrin and bicarbonate improve meloxicam solubility and bioavailability, enabling faster, sustained pain relief with rizatriptan.

Small-molecule FAO inhibitors suppress intracellular Mycobacteria by shifting host metabolism and boosting autophagy and mitochondrial ROS.

Modified mitragynine derivatives improve opioid receptor modulation for pain relief while reducing side effects and tolerance.

Alkali metal salt formation and particle-size milling improve solubility and systemic exposure of an AMPK-activating benzamide compound.

Topical or oral niacin promotes regeneration of bone resorbed by periodontitis or rheumatoid arthritis without relying on costly growth factors.

These isoquinoline sulfonamides target IgE-FcεRI binding to curb histamine release and treat allergic and asthma-related responses.

Direct allosteric AMPK activators based on substituted resorcylic acid improve metabolic treatment potential while avoiding mitochondrial toxicity.

Recombinant lymphotoxin alpha targets leukemic stem cells to overcome drug resistance and enable durable remission in myeloid leukemia.

Nucleophilic topical compounds scavenge cyanate from excess urea to reduce skin protein damage, dryness, itching, and pH imbalance.

Violacein-based feed compositions suppress Eimeria invasion and growth while avoiding resistance and residue issues in livestock coccidiosis.

CD200AR ligands counter tumor-driven immune suppression by downregulating PD-1 and CD200R1, improving vaccine response and tumor regression.

A mixed PEG-propylene glycol-povidone fill raises naproxen loading while maintaining pH control and soft gel shell compatibility.

Specific aromatic amino acids plus vitamin B6 improve skeletal muscle mass, strength, and function while avoiding costly protein supplements.

A non-aqueous cefovecin suspension uses propylene glycol dicaprylate/dicaprate and benzyl benzoate to limit caking while keeping injection easy.

A hyperbranched maltodextrin structure with high 1→6 linkages resists α-amylase digestion while maintaining soluble fiber content.

Benzene-1,3,5-tricarboxamide ester lipids stabilize lipid nanoparticles for efficient mRNA delivery while reducing oxidation-linked cytotoxicity.

A specific oral estetrol dose promotes hair growth in menopausal hair loss while aiming to avoid the safety limits of estrogen therapies.

Heating microbial cells at alkaline pH, then applying pH shock cycles, separates lipids without organic solvents, cutting waste and processing time.

Combining beta-glucan with a CD40 agonist boosts T cell-dependent anti-tumor immunity in poorly immunogenic pancreatic cancer.

Conjugated phosphorothioated oligonucleotides improve selective STAT3 and CEBPA modulation while supporting systemic delivery and immune stimulation.

Modular sigma-1 receptor agonist compounds improve receptor affinity and neuroprotection for cognitive and neurodegenerative disorders.

Selective HPK1 inhibitor compounds modulate T-cell and B-cell responses to support cancer treatment while limiting autoimmune risk.

Targeting overexpressed lncRNA LETN suppresses liver cancer cell growth by disrupting NPM1-linked rRNA production and nucleosome assembly.

Ginkgolide A offers a low-dose autism treatment approach that alleviates social, communication, and repetitive behavioral defects.

Stable mesylate, gentisate, and maleate cytisine salts enable lactose formulations with longer shelf life and less packaging burden.

A removable stereodirecting group enables intramolecular cyclization of tricyclic pyridone intermediates with high yield and optical purity.

Novel aryl glucoside SGLT1 inhibitors lower blood glucose through intestinal transport blocking, helping patients with renal impairment.

A benzofuran N-acylhydrazone derivative blocks tubulin polymerization to trigger apoptosis while improving solubility and activity in resistant cancer cells.

A biocompatible polymer with hyaluronic acid improves skin hydration and wrinkle reduction with longer-lasting effects and fewer applications.

A CBP/p300 CH1-domain modulator induces senescence or apoptosis in p53/Rb-defective cancers that resist current therapies.

NR4A1 agonists offer a non-opioid route to resolve post-operative and chemotherapy-induced neuropathic pain while reducing neuroinflammation.

Structured psilocybin dosing with pre- and post-session psychological support improves treatment adequacy for anxiety and related disorders.

Polyethylene glycol replaces ethanol in an aprepitant injection emulsion, improving storage stability and enabling use in ethanol-intolerant patients.

A cardiolipin-targeting peptidomimetic helps protect neurons, delay ALS symptom onset, and reduce axonal damage.

New antiparasitic compounds target T. gondii tissue cysts to treat chronic infection while reducing toxicity and allergic reactions.

Small molecules stabilize the GRB2 dimer interface to suppress RAS/MAP kinase signaling and support targeted cancer treatment.

An osmotic tablet uses a semipermeable membrane and push layer to sustain deutetrabenazine levels over 24 hours with once-daily dosing.

Hydrogel carriers localize immunosuppressive agents around peripheral nerve allografts to support regeneration while avoiding systemic risks.

A lipid and organic solvent composition keeps dutasteride levels stable for over a month while preventing precipitation and local irritation.

New indole and indazole TLR7/8/9 inhibitors improve stability, bioavailability, and therapeutic index for inflammatory disease treatment.

A xyloglucan core and pH-responsive coating limit small-intestine release and improve reliable colonic API delivery.

A carrier-based solid dispersion improves P2X4 inhibitor dissolution and stability while keeping impurities low and supporting better pharmacokinetics.

Targeting 4G4G and 4G5G PAI-1 genotypes, soy isoflavones help prevent asthma by lowering PAI-1 and airway inflammation.

Novel Formula (I) compounds improve JAK1 selectivity to treat asthma or COPD while reducing off-target JAK side effects.

Polymer binders capture uric acid in the gastrointestinal tract to lower serum levels and treat gout with fewer side effects.

A defined L-serine crystal form cuts moisture uptake while preserving fast dissolution, enabling stable storage and better pharmaceutical use.

Compounds built on substituted heterocycle scaffolds inhibit multiple Ras mutants and wildtype Ras to address low G12C prevalence and resistance.

Azaquinolone compounds are tuned for PARP1 selectivity and low hERG activity to improve cancer treatment efficacy while limiting off-target toxicity.

A stable liquid losartan composition uses specific excipients to match tablet bioavailability while enabling easier oral dosing and long-term storage.

CRISPR sgRNA and modified Cas9 compositions target lncEGFL7OS, EGFL7, and miR-126 to regulate angiogenesis beyond anti-VEGF resistance.

Intralymphatic delivery of multiple β cell autoantigens with vitamin D and anti-inflammatory compounds promotes durable immune tolerance with fewer systemic side effects.

A double crystal-form change produces fine drospirenone powder without grinding, preserving crystalline stability and bioavailability.

Selective inhibition of persistent VGSC currents curbs cancer cell invasion and metastasis while preserving cardiac function.

hUCB plasma modulates inflammatory and apoptotic responses to protect motor neurons and improve mononuclear cell viability in ALS.

Non-polymeric hydrophobic excipients replace complex OCAS matrices to give mirabegron extended release with stable dissolution for overactive bladder treatment.

Blending HMO syrup with GOS, FOS, or PDX creates a storage-stable, microbially safe liquid that avoids crystallization and drying.

High-dose NK1R antagonists such as aprepitant show human anti-cancer efficacy by inducing apoptosis and reducing tumor size.

Targets oxidative stress and amyloid aggregation to stabilize lens proteins, reduce disulfide bonds, and reverse presbyopia and cataracts.

Zirconia catalysts with high surface area convert c-CHDA to high-trans CHDA at lower cost, avoiding hard-to-handle thermal products.

AAV-delivered SOD expression protects inner ear hair cells from oxidative stress, enabling sustained prevention of noise, aging, and ototoxic hearing loss.

A super-chilled dextrose-salt ice slurry freezes subcutaneous fat for deeper reduction without general anesthesia or liposuction.

Liver-targeted polymethine dye delivery directs PKC inhibitors to treat septic cholestasis while reducing systemic immune suppression.

Controlled HPBCD substitution patterns overcome isomer mixtures to improve cholesterol solubilization and delivery for therapeutic use.

Targeted dsRNA silences AGT mRNA to lower angiotensinogen levels, offering a more specific route for hypertension treatment with fewer side effects.

Orally bioavailable estrogen receptor modulators block both AF1 and AF2, overcoming partial agonism and resistance in ER-associated disease treatment.

Dendrimer cannabinoid conjugates bypass first-pass metabolism to improve bioavailability and target neurons and activated microglia.

Modified branched siRNA targets SNCA mRNA for CNS delivery, improving stability and lowering alpha-synuclein in synucleinopathies.

Phosphorothioate and 2'-O-methyl miR-25 mimetics improve FKBP14 and ADAM-17 repression to better inhibit TGF-β-driven collagen in liver fibrosis.

A modified-release oral minoxidil formulation sustains serum levels to support hair regrowth while limiting rapid absorption and peak-related adverse effects.

Nanodomain topical formulations form a film on nails or skin, prolong antifungal release, improve keratin penetration, and limit systemic side effects.

Pyridine-N oxide acetamides inhibit IL-17 while improving oral or topical delivery through better solubility and in vivo exposure.

An intranasal diazepam formulation uses alkyl maltosides and carrier excipients to improve absorption consistency and reduce adverse reactions in children.

Topical ripasudil after descemetorhexis speeds endothelial healing, restores cell density, and improves corneal clarity in FECD.

Formula A-D-Y compounds inhibit VEGF, reduce cancer drug resistance, and enable topical ophthalmic treatment for diabetic retinopathy.

Spray-dried cysteamine microparticles in a thermoresponsive gel improve eye-drop stability, reduce irritation, and extend ocular release.

A dual liquid nicotine cartridge pairs water-miscible and immiscible solvents to improve lung deposition and reduce upper airway harshness.

Targeting miR-132 with the oligonucleotide CDR132L helps reverse cardiac remodeling, improve left ventricular function, and attenuate fibrosis.

SIK-modulating compounds increase bone formation and bone mass while avoiding daily injections and lowering hypercalcemia risk in osteoporosis treatment.

Targeting mPGES-1 blocks PGE2-driven inflammation and pain, offering a new treatment approach for chronic prostatitis syndrome.

CRISPR knockout of CISH improves CAR-T cell persistence and engraftment while reducing immunogenicity and graft-versus-host disease.

Controlled pH and shear-induced protein hydrogel formation creates biodegradable microcapsules that stay stable in liquids and protect sensitive actives.

Higher-solubility purine-pyrimidine aqueous formulations cut reconstitution time and dose volume, easing administration for MDS patients.

Selective norepinephrine inhibitors such as reboxetine reduce cataplexy attacks while improving concentration and sleep quality.

A new Form A polymorph resists interconversion under heat and humidity while improving solubility and storage stability for drug formulation.

Targeted polynucleotides recruit spliceosomal moieties to pre-mRNA, improving splicing control and cancer gene regulation.

Adding beta-1,3'-galactosyllactose to infant formula helps block toxin adhesion and strengthen the intestinal barrier.

Preoperative PKC inhibition shrinks uveal melanoma tumors, enabling eye-preserving treatment and reducing enucleation risk.

IV dextroamphetamine and lisdexamfetamine rapidly reverse dexmedetomidine sedation, restoring consciousness while limiting hypotension and re-sedation.

Novel phthalazine derivatives activate PKM2 and PKLR while improving ADME and safety, addressing limits of existing pyruvate kinase therapies.

Controlling metal levels and using ion exchange removes neutral protease, yielding collagenase with higher purity, stability, and reproducibility.

Thermoresponsive surfactant-alcohol gel balances syringeability, mucoadhesion, and sustained release of poorly water-soluble agents.

A polymer-matrix amorphous BMS-986165 formulation preserves solubility and bioavailability under elevated gastric pH while enabling extended release.

Selective OX1 antagonist compounds extend receptor occupancy while preserving OX2 function for addictive and CNS disorder treatment.

Formula I prodrugs modulate eIF2B to attenuate the integrated stress response, reducing cellular stress in ISR-related diseases.

An mTOR inhibitor composition suppresses cancer cell growth, induces autophagy, and helps address resistance in colorectal cancer treatment.

Friomaramide blocks Plasmodium falciparum sporozoite invasion and liver-stage development while remaining non-toxic to human hepatocytes.

A modified pregnenolone selectively inhibits overactive CB1 receptors to improve cognition without the adverse effects of conventional treatments.

Tradipitant blocks NK-1 signaling to curb cytokine storm, reduce lung injury and fibrosis, and shorten respiratory support in viral infection.

Specific siRNA target regions in MURF1 mRNA improve gene suppression and support treatment of muscle mass loss, weakness, and dysfunction.

Blocking G-CSF receptor signaling helps reduce lung inflammation in ARDS and may lower disease severity and intensive care burden.

High-concentration topical Zileuton delivers local anti-inflammatory action in skin disease while avoiding the hepatotoxicity of oral dosing.

Selective PRMT5 inhibition reverses aberrant gene silencing, boosts p53 and γ-globin expression, and supports treatment of cancer and SCD.

Plant fruit vesicles bind and protect nucleic acids, improving reproducible cellular uptake without complex delivery components.

Subcutaneous mosunetuzumab with polatuzumab vedotin maintains lymphoma response while reducing cytokine-driven toxicity and infusion reactions.

Dual EGFR and c-Met blockade with a bispecific antibody plus a 3rd-generation EGFR inhibitor helps limit relapse and extend response.

Blocking the LINC complex inhibits durotaxis to target fibrosis mechanisms, while also reducing metastasis and supporting wound healing.

Dose-adjusted lurbinectedin with anti-emetic support treats refractory SCLC while managing hepatotoxicity and hematologic toxicity.

Treprostinil treatment for ILD improves forced vital capacity and pulmonary function where existing approved drugs show limited efficacy.

Aprotic polar solvents and ionization stabilizers keep levothyroxine stable while enabling sustained subcutaneous delivery beyond oral GI limits.

Targeting conserved influenza A genome regions with inhaled RNAi agents helps suppress viral mRNA across strains and improve pulmonary delivery.

Bicyclic urea compounds tune SIK1, SIK2, and SIK3 binding to improve kinase selectivity while limiting off-target effects.

Topical potassium isomerized linoleate reduces microbial load at skin and mucosal entry points to ease neuroinflammatory symptoms.

A high-purity Formula I CSF-1R inhibitor improves selectivity, limits off-target kinase toxicity, and supports stable pharmaceutical compositions.

Encapsulated hemoglobin with ATP and related metabolic agents improves oxygen delivery, circulatory stability, and storage for hemorrhagic shock.

A dry powder nasal epinephrine formulation improves stability, avoids needles, and supports fast, reliable dosing in emergencies.

A natural matrix of turmeric, AKBA, beta-caryophyllene, and Kaempferia extracts targets joint inflammation while reducing side effects.

A hinged charging case and replaceable nicotine tip simplify refilling and charging, making the vaporizer more intuitive for smokers.

A pH-controlled nebivolol oral liquid uses solubilizers and sweeteners to improve bioavailability, taste, and dosing compliance.

A bispecific EGFR-HER3 antibody linked to camptothecin improves tumor cell killing while helping limit resistance from single-target ADC therapy.

CRF1 receptor blockade reduces ACTH, 17OHP, and A4 while shrinking TART and OART, offering a non-steroidal option for CAH.

A 5′-O-acetoacetyl diacetyluridine prodrug improves oral uridine delivery while co-delivering acetoacetate for mitochondrial energy support.

A nebulized flecainide-cyclodextrin formulation enables rapid cardioversion while avoiding the high-dose adverse events of oral and IV therapy.

Engineered gummy segmentation and sensor-guided molding improve dose consistency, easy separation, and compliance for users who struggle with pills.

An acrylic drug-in-adhesive patch delivers SGLT2 inhibitors through skin for 7 days, bypassing first-pass liver metabolism and reducing side effects.

Oral delivery agents improve GI uptake of PCSK9 antisense conjugates, while GalNAc liver targeting helps lower LDL with reduced kidney exposure.

A breath-activated mesh nebulizer kit improves pulmonary drug delivery efficiency and shortens high-dose inhalation time for better compliance.

Benzofuran TRPM3 antagonists are tuned to relieve pain and inflammatory hypersensitivity while improving safety and pharmacokinetic balance.

Using solid GDL with HPMC, this vaginal formulation enables slow gluconic acid release to reduce biofilms with better stability and low resistance risk.

An oral AT2 receptor agonist, C21, addresses IPF progression by restoring lung function while avoiding the side effects of current antifibrotics.

Structural changes at camptothecin's 7-position improve solubility and antitumor activity while helping limit toxicity and resistance.

Liver-targeted APOC3 RNAi conjugates suppress hepatocyte gene expression to lower triglycerides when conventional therapies are insufficient.

ATA combined with nucleases breaks protein-DNA interactions in resistant biofilms, improving disaggregation in chronic wound treatment.

Ex vivo expanded cord blood Treg cells use cytokine-driven culture to boost cell numbers while preserving immunosuppressive function after cryopreservation.

Selective small molecules inhibit CYP11A1 to block steroid biosynthesis while aiming to preserve antitumor activity with fewer side effects.

Cryogenic impact milling and centrifugal distillation produce reproducible cannabinoid nanoparticles with high purity and controlled size.

Daily COMPOUND A dosing from 0.1-15 mg improves cancer treatment benefit while limiting adverse events and supporting combination use.

A Polypodium leucotomos and Larix decidua oral composition helps counter UV-driven oxidative stress, inflammation, and photoaging.

By inhibiting the NLRP3 inflammasome, cannabidiol lowers IL-1β and IL-6 while reducing pericardial effusion and thickness in recurrent pericarditis.

A multilayer amnion graft uses enriched coatings to stabilize bioactive factor levels and improve consistency in wound healing and tissue repair.

A small-molecule LTK inhibitor expands targeted treatment options for CLIP1-LTK fusion-positive solid tumors, including non-small cell lung cancer.

Controlled particle size, wetting, and sonication keep triamcinolone suspensions resuspendable and clog-free for 30-gauge ocular injection.

A low-zinc arginine formulation protects tooth enamel from gastric acid erosion while avoiding the astringent taste of high-zinc toothpaste.

Using β-glucan to treat acne and steroid-dependent dermatitis helps reduce irritation, avoid resistance, and speed skin healing.

Anti-c-kit and CD47-based conditioning clears marrow niches for donor stem cell engraftment without radiation, chemotherapy, or severe toxicity.

Azo-linked AhR agonist prodrugs are reduced in the colon to localize anti-inflammatory treatment and modulate gut-brain disorders.

State-based palovarotene dosing uses maintenance and flare-up phases to reduce heterotopic ossification and flare-up severity in FOP.

Liquid-liquid phase separation helps multivalent ligands cluster cell surface receptors beyond valency limits while improving specificity and selectivity.

Dexamethasone inhibits ASD extracellular vesicle-driven IFN-gamma secretion to reduce chronic inflammation linked to autism symptoms.

Selective HDAC6 inhibitors combined with IMiDs improve multiple myeloma treatment by reducing dose-limiting toxicity and boosting efficacy.

A liquid-to-gel phenylephrine eye formulation boosts ocular residence time for rapid, sustained mydriasis with fewer doses and side effects.

Defined antiviral enantiomers improve potency and exposure while reducing off-target carbonic anhydrase activity in herpes treatment.

A monohydrate TRK inhibitor form slows aqueous dissolution and resists polymorphic conversion, enabling more stable extended-release formulations.

Low-molecular cycloalkane-1,3-diamine compounds disrupt menin-MLL binding to block abnormal gene activation in MLL-rearranged leukemia.

Controlled oral minoxidil release maintains effective serum levels over time, improving hair regrowth while reducing peak-related adverse effects.

Combining XOS, inulin, and magnesium maintains Bifidobacterium and gut barrier integrity while reducing high-inulin gas and formulation limits.

Selective compounds inhibit CDK2/cyclin E and A complexes to curb aberrant DNA replication in CCNE1 or CCNE2 amplified cancers.

A polymer-surfactant ticagrelor solid dispersion overcomes low solubility and permeability to improve dissolution and bioavailability.

Small-molecule PP2A activators suppress MYC and kinase signaling to treat resistant cancers and restore chemotherapy sensitivity.

Azole compounds modulate CYP51 and related enzymes to accumulate sterol intermediates, drive OPC maturation, and promote remyelination.

Electrospun polymeric micro-/nanofibers improve echinochrome A solubility and stability while enabling controlled release and targeted delivery.

Bridged epidithiodioxopiperazine compounds mimic 2-Cys-Prx to curb smooth muscle hyperplasia, support endothelial recovery, and lower toxicity.

Lipid and polymer excipients help d4-domperidone raise bioavailability while lowering Cmax and reducing QT prolongation risk.

Dissociated endocrine progenitors are reaggregated with pathway inhibitors to form viable beta cell clusters with glucose-responsive insulin secretion.

Fractionated anti-CD20/anti-CD3 dosing across treatment cycles reduces cytokine release and tumor lysis risk while preserving efficacy.

Modified oligonucleotides target PRNP RNA to lower prion protein levels, helping slow neurodegenerative disease progression.

A DPP4 inhibitor linked to a chelator and radionuclide improves myocarditis imaging specificity by targeting inflammatory cells over non-target tissue.

A two-phase oral minoxidil release profile balances fast absorption with steadier blood levels to reduce peak-related adverse effects.

A bifunctional heterocyclic compound drives HSP90-linked KRAS ubiquitination and degradation, extending targeting beyond G12C to G12D.

A solubilized soft gel vaginal estradiol form improves compliance, reduces discharge, and supports VVA symptom relief with adjustable dosing.

Topical compounds block cancer drug binding in skin to prevent toxicities and help maintain dosing continuity during treatment.

Biodegradable tail structures in lipid nanoparticles improve stability, bioavailability, and degradation for more effective drug delivery.

A floating alginate and cellulose polymer raft enables 6-24 hour stomach drug release with simpler, lower-cost manufacturing.

By linking 13-cis-retinoic acid with ascorbic acid, this conjugate improves water solubility, lowers dosage, and boosts anticancer activity.

Spray-dried amorphous dispersions and solubilized formulations help poorly soluble Compound (I) reach therapeutic plasma levels with stable oral delivery.

Selective fast-myosin inhibition reduces muscle breakdown and inflammation while preserving function in Duchenne and related neuromuscular diseases.

Minimal ARRDC1 domains free vesicle space for safer ARMM delivery of large cargos such as Cas9 and guide RNAs with lower immune response.

Nitrogen-substituted CD38 inhibitor compounds improve solubility, half-life, and in vivo exposure while reducing drug-drug interaction risk.

By removing vulnerable RNA ends, circular polyribonucleotides boost translation, reduce immune recognition, and extend cellular persistence.

Lecithin-coated calcium phosphate nanoparticles improve bisphosphonate uptake and bioavailability while reducing oral gastrointestinal side effects.

This case shows how a formula I fused ring compound uses tumor expression and methylation markers to support more precise treatment.

Formula I compounds target drug-resistant HIV while improved pharmacokinetics may support less frequent dosing.

Modified oligonucleotides hybridize with SCN2A RNA to lower RNA and protein levels linked to seizures and cognitive dysfunction.

Basic deprotection of a silicon-linked group produces the API derivative with low impurities and high yield for mass synthesis.

Galactomannans bind SARS-CoV-2 virions to limit cell entry, reduce infectivity and viral RNA, and enhance IgG antibody titers.

Standard mammography can improve coverage but drive overscreening; this lipid panel segments individuals by risk for tailored screening.

Double-stranded RNA agents bind APCS transcripts and trigger RISC cleavage to lower SAP expression and amyloid load.

This case uses ligand changes to tune reduction potential, limit albumin binding, and improve copper release to the CNS.

This case shows how tailored RAF inhibitor structures suppress RAS-ERK signaling and tumor growth while avoiding paradoxical ERK activation.

A CBDA-focused cannabinoid composition targets microglial activation and neuroinflammation with THC limited below 1%.

This case uses defined sialic acid concentration and pH ranges to block SARS-CoV-2 attachment and simplify dosing.

This case combines a selective HDAC3 inhibitor with checkpoint blockade to increase MHC II antigen presentation and immune response.

High-pressure homogenization creates stable crystalline nanoparticles for lung delivery, helping limit systemic adverse reactions.

This case examines iloperidone for elderly Parkinson’s patients, balancing psychosis relief with manageable side effects.

A coordinated aripiprazole, ALNCD, and LAI regimen reaches therapeutic levels within 24 hours and maintains them for at least 21 days.

This case shows how reversible, non-covalent BTK binding targets C481S-mutant B-cell cancers while reducing adverse effects.

This case uses bicyclic heterocycles to block MRGPRX2, reducing mast cell degranulation and inflammatory mediator release.

This case combines BET and JAK inhibitors to address epigenetic and JAK-STAT pathways, reducing fibrosis and improving survival.

This case uses eIF3f and eIF3m modulation to reduce RAN protein accumulation while preserving normal translation.

This case addresses friable or chronic wounds with a polymer dressing that supports tissue integration while delivering immune and growth signals.

This case shows how SHP2-binding PROTACs recruit VHL E3 ligase to drive ubiquitination and proteasomal degradation for cancer treatment.

This case combines reversible P2Y12 inhibition with thrombin inhibition for rapid stent thrombosis control and reduced bleeding risk.

Benzodiazepine compounds target RSV N-protein activity with improved stability and safety.

This case uses selective ATR inhibitor compounds with chemotherapy to block DNA repair and amplify cancer cell death.

Vitamin K2 combines targeted calcium management with protective formulation measures to address calcification and bioavailability.

This case combines dimethylglycine with amylopectin to support nutrient and oxygen supply, hair density, and scalp condition.

Formula I compounds selectively bind TYK2 to treat autoimmune and inflammatory disorders while limiting effects on JAK2 and other kinases.

These pyridinone derivatives trigger premature HIV protease activation, killing infected cells while sparing HIV-naïve cells.

Sequence-specific oligonucleotides inhibit amphiregulin mRNA, while nanoparticles improve stability and delivery for fibrosis therapy.

This case pairs bupropion with dextromethorphan to raise plasma levels, limit adverse events, and support less frequent dosing.

Amorphous asiatic acid tromethamine salt improves solubility and bioavailability compared to crystalline forms.

A pharmaceutical composition combining sarpogrelate and Vaccinium myrtillus extract inhibits auditory hair cell death.

TLR9 antagonists target inflammatory pathways to reduce muscle pain and prevent relapses in rhabdomyolysis patients.

Composite pharmaceutical formulation with solubilizers and antioxidants reduces pharmacokinetic variability and adverse reactions.

Antisense oligonucleotides modulate ATP7B splicing to correct copper handling defects, replacing chelation therapies with adverse effects.